Human Gut Microbiota and Drug Metabolism

被引:0
作者
Archana Pant
Tushar K. Maiti
Dinesh Mahajan
Bhabatosh Das
机构
[1] National Institute of Immunology,Molecular Genetics Lab
[2] NCR Biotech Science Cluster,Regional Centre for Biotechnology
[3] Translational Health Science and Technology Institute,Molecular Genetics Laboratory
[4] NCR Biotech Science Cluster,Chemistry and Pharmacology Lab
[5] Translational Health Science and Technology Institute,undefined
[6] NCR Biotech Science Cluster,undefined
来源
Microbial Ecology | 2023年 / 86卷
关键词
Gut microbiome; Drug metabolism; Xenobiotics; Biotransformation; Genetic ecology;
D O I
暂无
中图分类号
学科分类号
摘要
The efficacy of drugs widely varies in individuals, and the gut microbiota plays an important role in this variability. The commensal microbiota living in the human gut encodes several enzymes that chemically modify systemic and orally administered drugs, and such modifications can lead to activation, inactivation, toxification, altered stability, poor bioavailability, and rapid excretion. Our knowledge of the role of the human gut microbiome in therapeutic outcomes continues to evolve. Recent studies suggest the existence of complex interactions between microbial functions and therapeutic drugs across the human body. Therapeutic drugs or xenobiotics can influence the composition of the gut microbiome and the microbial encoded functions. Both these deviations can alter the chemical transformations of the drugs and hence treatment outcomes. In this review, we provide an overview of (i) the genetic ecology of microbially encoded functions linked with xenobiotic degradation; (ii) the effect of drugs on the composition and function of the gut microbiome; and (iii) the importance of the gut microbiota in drug metabolism.
引用
收藏
页码:97 / 111
页数:14
相关论文
共 890 条
  • [61] Javdan B(2020)Serine proteases at the cutting edge of IBD: focus on gastrointestinal inflammation FASEB J 34 7270-3664
  • [62] Lopez JG(2012)Protease-activated drug development Theranostics 2 156-217
  • [63] Chankhamjon P(2019)Recent advances in the development of legumain-selective chemical probes and peptide prodrugs Biol Chem 400 1529-176
  • [64] Lee YCJ(2020)Protease-activated prodrugs: strategies, challenges, and future directions FEBS J 287 1936-3950
  • [65] Hull R(2014)Mechanism-based inhibitors of glycosidases: design and applications Adv Carbohydr Chem Biochem 71 297-171
  • [66] Wu Q(2013)The abundance and variety of carbohydrate active enzymes in the human gut microbiota Nat Rev Microbiol 11 497-526
  • [67] Wang X(2015)Structure and inhibition of microbiome b-glucuronidases essential to the alleviation of cancer drug toxicity Chem Biol 22 1238-901
  • [68] Chatterjee S(2009)Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile Int J Exp Pathol 90 489-1576
  • [69] Donia MS(2006)Pharmacogenetics of irinotecan metabolism and transport: an update Toxicol In Vitro 20 163-1733
  • [70] Kerimi A(2001)Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients Clin Cancer Res 7 1136-298